The Shanghai No. 1 People's Hospital, where a fake drug caused eye infections in 61 out of 116 patients, has paid compensation to recently discharged patients.
As reported in the September 15th issue of the Shanghai Daily, a payout was made by the hospital to patients that were treated with a counterfeit of Roche's drug Avastin that developed complications due to the medication.
Tests by Shanghai officials and Roche confirmed the drug was fake.
According to the Shanghai Daily:
• The minimum paid was 2,000 yuan (US$299), although some patients discharged early this month were not compensated.
• The 61 patients were among 116 people who received the medicine at Shanghai No. 1 People's Hospital on September 6 and 8.
• After the injections, the patients reported eye inflammations and poor vision and were quickly hospitalized. Seventeen patients with severe reactions underwent surgery. The rest received injections to treat the infections.
The issue of fraudulent, adulterated, substandard and counterfeit medications continues to grow and impact the legitimate supply chains and professionally provided health care.
When health care consumers cannot reliably depend upon medication treatment made by health care professionals to be safe and efficacious the entire population suffers.
All members of the global pharmaceutical supply chain need to deploy solutions and technologies to protect their inventories and health care consumers.
To read the article, visit: http://www.shanghaidaily.com/article/?id=450218&type=Metro#ixzz10vZKjmk1.
To learn more about pharmaceutical anti-counterfeiting technologies, visit: http://www.xstreamsystems.net/.
As reported in the September 15th issue of the Shanghai Daily, a payout was made by the hospital to patients that were treated with a counterfeit of Roche's drug Avastin that developed complications due to the medication.
Tests by Shanghai officials and Roche confirmed the drug was fake.
According to the Shanghai Daily:
• The minimum paid was 2,000 yuan (US$299), although some patients discharged early this month were not compensated.
• The 61 patients were among 116 people who received the medicine at Shanghai No. 1 People's Hospital on September 6 and 8.
• After the injections, the patients reported eye inflammations and poor vision and were quickly hospitalized. Seventeen patients with severe reactions underwent surgery. The rest received injections to treat the infections.
The issue of fraudulent, adulterated, substandard and counterfeit medications continues to grow and impact the legitimate supply chains and professionally provided health care.
When health care consumers cannot reliably depend upon medication treatment made by health care professionals to be safe and efficacious the entire population suffers.
All members of the global pharmaceutical supply chain need to deploy solutions and technologies to protect their inventories and health care consumers.
To read the article, visit: http://www.shanghaidaily.com/article/?id=450218&type=Metro#ixzz10vZKjmk1.
To learn more about pharmaceutical anti-counterfeiting technologies, visit: http://www.xstreamsystems.net/.
Posts
No comments:
Post a Comment